Absci Corp ABSI
We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. We focus on underexplored mechanisms where unmet medical need is high and competition is low.
We have advanced our first two programs from AI design to IND (or foreign equivalent) in around two years with a total investment of approximately $15 million per program, compared to an industry average of 4–6 years at a cost of greater than $50 million. This combination of underexplored target selection and capital-efficient execution is central to our strategy.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $4.5M | $5.7M | $4.5M | $4.0M | $4.1M | — |
| R&D | $81.4M | $63.9M | $48.1M | $58.9M | $44.6M | $11.4M | — |
| SG&A | $35.1M | $36.2M | $37.8M | $40.6M | $28.8M | $5.5M | — |
| Total operating expenses | $123.1M | $113.4M | $121.2M | $112.5M | $80.0M | $18.1M | — |
| Operating income | -$120.3M | -$108.9M | -$115.5M | -$106.8M | -$75.2M | -$13.3M | — |
| Interest expense | $209.0K | $565.0K | $1.0M | $972.0K | $3.4M | $634.0K | — |
| Pre-tax income | -$115.1M | -$103.0M | -$110.5M | -$105.4M | -$109.9M | -$14.4M | — |
| Income tax | $69.0K | $70.0K | $100.0K | $461.0K | $8.9M | $0 | — |
| Net income | -$115.2M | -$103.1M | -$110.6M | -$104.9M | -$101.0M | -$14.4M | — |
| EPS, basic | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 | -3.19 | — |
| EPS, diluted | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 | -3.19 | — |
| Shares, diluted (wtd. avg.) | 136.8M | 110.2M | 92.0M | 90.8M | 49.7M | 15.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.0M | $41.2M | $89.7M | $76.8M | $279.9M | $71.7M | $13.9M |
| Short-term investments | $124.3M | $71.2M | — | — | — | — | — |
| Receivables | — | $0 | $2.2M | — | — | — | — |
| Total current assets | $149.6M | $133.8M | $120.6M | $186.9M | $273.1M | $73.2M | — |
| Goodwill | — | — | $0 | $21.3M | $21.3M | $0 | — |
| Other intangibles | $41.5M | $44.9M | $48.3M | $51.6M | $55.0M | $0 | — |
| Total assets | $216.3M | $213.6M | $217.3M | $321.0M | $426.2M | $88.6M | — |
| Accounts payable | $2.8M | $2.9M | $1.5M | $2.4M | $8.4M | $2.1M | — |
| Total current liabilities | $22.8M | $28.7M | $29.6M | $30.3M | $33.9M | $10.1M | — |
| Long-term debt | — | $4.0M | $7.9M | $10.9M | $3.5M | — | — |
| Total liabilities | $26.8M | $34.5M | $41.1M | $46.6M | $60.1M | $21.6M | — |
| Retained earnings | -$624.8M | -$509.6M | -$406.5M | -$295.9M | -$191.0M | -$90.1M | — |
| Total equity | $189.4M | $179.1M | $176.2M | $274.4M | $366.1M | -$89.4M | -$41.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$92.9M | -$72.4M | -$64.6M | -$81.3M | -$60.6M | -$11.0M | — |
| Depreciation and amortisation | $11.7M | $13.4M | $14.0M | $13.0M | $6.7M | $1.1M | — |
| Stock-based compensation | $18.3M | $19.5M | $11.4M | $12.5M | $10.6M | $420.0K | — |
| Capital expenditure | $1.1M | $404.0K | $860.0K | $16.2M | $38.0M | $2.2M | — |
| Investing cash flow | -$50.2M | -$41.6M | $81.9M | -$127.0M | -$67.4M | -$2.2M | — |
| Financing cash flow | $105.9M | $82.5M | -$4.5M | $5.2M | $336.2M | $71.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001672688-26-000068.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $4.1M | $4.0M | $4.5M | $5.7M | $4.5M | $2.8M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$14.4M | -$101.0M | -$104.9M | -$110.6M | -$103.1M | -$115.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $46.63B | 35.6x | 5.9% |
| INCY | INCYTE CORP | $23.12B | 18.1x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $18.68B | 43.8x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $16.49B | — | -0.9% |
| OABI | OmniAb, Inc. | $677.5M | — | -29.3% |
| NRC | NRC HEALTH | $485.1M | 0.4x | -4.0% |
| ONMD | OneMedNet Corp | $279.2M | — | 111.4% |
| MXCT | MAXCYTE, INC. | $144.5M | — | -5.7% |